New oligo-beta-(1,3)-glucan derivatives as immunostimulating agents.
Oligo-beta-(1,3)-glucans were chemically modified in order to introduce a structural variation specifically on the reducing end of the oligomers. The impact of well defined structural modulations was further studied on cancer cells and murin models to evaluate their cytotoxicity and immunostimulating potential.
Descroix
Karine
K
Ecole Nationale Supérieure de Chimie de Rennes, CNRS, UMR 6226, Avenue du Général Leclerc, CS 50837, 35708 Rennes Cedex 7, France.
Vetvicka
Vaclav
V
Laurent
Isabelle
I
Jamois
Frank
F
Yvin
Jean-Claude
JC
Ferrières
Vincent
V
D000276:Adjuvants, Immunologic / Q000737:chemistry* / Q000494:pharmacology*; D000818:Animals; D002236:Carbohydrate Conformation; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000276:immunology; D008358:Mannose / Q000737:chemistry* / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D010587:Phagocytosis / Q000187:drug effects; D047071:beta-Glucans / Q000737:chemistry* / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D007376:Interleukin-2; D047071:beta-Glucans; D008358:Mannose